{"Clinical Trial ID": "NCT01326481", "Intervention": ["INTERVENTION 1:", "Carotuximab (TRC105) Plus Capecitabine", "All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg per week) Capecitabine: oral (1 000 mg/m2 BID)"], "Eligibility": ["Incorporation criteria:", "A strong histologically proven cancer for which curative treatment is not available (Part 1 only)", "Histologically proven metastatic Her-2 negative breast cancer (part 2 only)", "A disease that can be measured according to the RECIST criteria 1.1 (Part 2 only)", "Willingness and ability to consent to self-participation in the study", "A progressive or recurrent disease after previous systemic chemotherapy", "- 18 years", "ECOG performance status of 0 or 1", "- Resolution of all acute toxic effects of pre-ICN treatment CTCAE Grade 1 or baseline (except alopecia)", "Adequate function of the organ", "- Exclusion criteria:", "Previous treatment with more than one regimen of systemic chemotherapy for metastatic diseases.", "Previous treatment with TRC105", "History of hypersensitivity to antimetabolite treatment", "\u2022 Reception of a research officer within 28 days of the start of treatment under study", "\u2022 Prior surgery (including open biopsy), radiotherapy or systemic therapy within 28 days of initiation of study therapy", "\u25cf Minor surgical procedures within 14 days prior to the first dose of TRC105", "\u2022 History of brain metastases, spinal cord compression or carcinoma meningitis, or new signs of brain or leptomenal disease", "Angina, MI, symptomatic congestive heart failure, stroke, transient ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG in the last 6 months", "Uncontrolled chronic hypertension defined as systolic > 140 or diastolic > 90 despite optimal treatment", "Previous medical history of acquired or hereditary coagulopathy, including patients with known hereditary haemorrhagic telangia", "\u2022 Thrombolytic or anticoagulant use (except to maintain i.v. catheters) within 10 days prior to the first dose of TRC105", "\u25cf Cardiac dysrhythmias of NCI CTCAE Grade 2 in the last month", "- Haemorrhage within 28 days of initiation of treatment under study", "\u2022 Unhealed injuries within 28 days of initiation of treatment under study", "The history of peptic ulceration or gastritis in the last 6 months, unless treatment for state and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of initiation of treatment.", "The known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)", "known number of active viral or non-viral hepatitises", "History of hypersensitivity reaction to human antibodies or mice", "- Lung cancer with central thoracic lesions", "Pregnancy or lactation"], "Results": ["Performance measures:", "To determine the maximum tolerated dose of TRC105 in combination with capecitabine", "To evaluate the safety and limit toxicity of the dose per dose cohort and encode all terms used in MedDRA version 14.1.", "Time limit: 1.5 and a half years", "Results 1:", "Title of the arm/group: Carotuximab (TRC105) More Capecitabine", "All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg per week) Capecitabine: oral (1 000 mg/m2 BID)", "Total number of participants analysed: 6", "Type of measure: Number of participants", "Unit of measure: Participants Patients with DLT at 7.5 mg/kg: 0 0.0%", "* DLT-free patients at 7.5 mg/kg: 3 50.0%", "Patients with DLT at 10 mg/kg: 0 0.0%", "* Patients without DLT at 10 mg/kg: 3 50.0%"], "Adverse Events": ["Undesirable Events 1:", "Total: 6/19 (31.58 per cent)", "Febrile neutropenia [1]1/19 (5.26%)", "Fatigue [1]1/19 (5.26%)", "Pyrexia [1]1/19 (5.26%)", "Fracture [1]1/19 (5.26%)", "- Hip fracture [1]1/19 (5.26%)", "Headache [2]1/19 (5.26%)"]}